Compare FMS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMS | UTHR |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 20.3B |
| IPO Year | 1996 | 1999 |
| Metric | FMS | UTHR |
|---|---|---|
| Price | $23.53 | $493.41 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $30.00 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 415.8K | 411.6K |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | 8.62 | ★ 16.08 |
| EPS | 2.86 | ★ 26.38 |
| Revenue | ★ $23,046,819,198.00 | $3,128,400,000.00 |
| Revenue This Year | $2.12 | $13.64 |
| Revenue Next Year | $2.92 | $5.78 |
| P/E Ratio | ★ $15.87 | $18.73 |
| Revenue Growth | 2.10 | ★ 13.50 |
| 52 Week Low | $22.05 | $266.98 |
| 52 Week High | $30.46 | $496.73 |
| Indicator | FMS | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 65.89 |
| Support Level | $22.63 | $474.59 |
| Resistance Level | $24.20 | $489.99 |
| Average True Range (ATR) | 0.27 | 10.16 |
| MACD | 0.10 | -0.69 |
| Stochastic Oscillator | 59.23 | 91.64 |
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.